uniQure Announces Financial Results for Third Quarter 2015 and Provides Update on Product Pipeline and Company Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
uniQure (QURE) Ests and PT Cut After Dropping Glybera - Jefferies
December 1, 2015 9:49 AM ESTJefferies analyst, Eun Yang, reduced the price target on uniQure BV (NASDAQ: QURE) to $36 vs $40 previously. The drop takes into account the loss of revenue from the removal of Glybera and increasing the discount rate to 13% (from 12%) to reflect yet-to-be proven commercial potential/success of gene therapy products. No change to... More
uniQure BV (QURE) Sell-Off 'Unfounded' - Oppenheimer
December 1, 2015 7:11 AM ESTOppenheimer Christopher Marai views yesterday's nearly 17% sell-off in uniQure BV (NASDAQ: QURE) unfounded. As such, the firm reiterated an Outperform rating and price target of $50.
uniQure reported 3Q15, ending the quarter with $215M in cash.
Marai commented, "Importantly, QURE clarified the... More
uniQure BV (QURE) Ph1/2 MPS3b Has Strong Reception at ICSS - Cowen
November 30, 2015 7:44 AM ESTCowen analyst Ritu Baral reiterated an Outperform rating on uniQure BV (NASDAQ: QURE) Ph1/2 12 mo. MPS3b AMT-110 data was presented again at ICSS Friday and was very well received by MPS3 KOLs.
Baral commented, "The trial PI noted 18 more mos. of... More
uniQure (QURE) Misses Q3 EPS by 3c
November 30, 2015 7:34 AM ESTuniQure (NASDAQ: QURE) reported Q3 EPS of (EUR0.67), EUR0.03 worse than the analyst estimate of (EUR0.64). Revenue for the quarter came in at EUR3.15 million versus the consensus estimate of EUR2.8 million.
For earnings history and earnings-related data on uniQure (QURE) click here.
... More
